Stereotactic body radiotherapy achieved durable local control exceeding 80% beyond 4 years and a median overall survival of 93.8 months in patients with extracranial oligometastatic disease.
Cohort (n=259)
No
Does SBRT provide durable local control and overall survival in patients with extracranial oligometastatic disease?
SBRT provides durable local control and prolonged overall survival in carefully selected patients with extracranial oligometastatic disease.
Background Extracranial oligometastatic disease, defined as up to five metastases, represents an intermediate cancer state with potential for long-term control. Stereotactic body radiotherapy (SBRT) is a non-invasive treatment associated with high local control, limited toxicity, and the ability to delay systemic therapy. This study reports institutional outcomes of SBRT across oligometastatic scenarios. Materials and methods We retrospectively analyzed 259 patients with 401 extracranial oligometastatic lesions from solid tumors treated with SBRT between 2016 and 2022. Patients were classified according to the ESTRO–EORTC consensus as oligorecurrence, oligoprogression, or oligopersistence, and as synchronous or metachronous. The eligibility criteria included ECOG 0–1, life expectancy > 6 months, ≤ 5 treatment-naïve extracranial metastases, and no intracranial disease. Survival outcomes were estimated using the Kaplan–Meier method. Results After a median follow-up of 68.7 months, SBRT achieved durable local control exceeding 80% beyond 4 years across all metastatic sites, with lung and lymph node lesions showing the best outcomes. Overall disease control declined due to new metastases; however, over 40% of lesions remained progression-free at 6 years. Superior outcomes were observed in patients with genuine oligometastatic disease, de novo or synchronous presentation, and fewer treated lesions. Median overall survival (OS) was 93.8 months (95%CI 81.1–106.4) and was longer in patients with initially locoregional disease and prostate cancer. Conclusions In this retrospective single-center experience, SBRT achieved durable local control with acceptable toxicity in selected patients with extracranial oligometastatic disease. These findings are consistent with previously published series and support the role of SBRT as a metastasis-directed approach in carefully selected patients. Prospective studies are needed to better define prognostic subgroups and optimize patient selection.
Méndez et al. (Sat,) conducted a cohort in Extracranial oligometastatic disease (n=259). Stereotactic body radiotherapy (SBRT) was evaluated on Overall survival. Stereotactic body radiotherapy achieved durable local control exceeding 80% beyond 4 years and a median overall survival of 93.8 months in patients with extracranial oligometastatic disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: